Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study
Objective: To assemble an international, multi-stakeholder Delphi panel to seek consensus on trial methodology for an adaptive trial platform investigating disease modifying therapies (DMTs) in…Exploring the Potential Anti-dementia Roles of Selected Herbal Anti-inflammatory Remedies in Parkinson’s Disease: Hopes and Challenges
Objective: To evaluate anti-dementia properties of the selected herbal anti-inflammatory remedies Background: Parkinson’s disease (PD) is the most common age-related neurodegenerative disease after Alzheimer’s disease.…Quantitative systems pharmacology modelling of Parkinson’s disease to compare anti-α-synuclein therapeutics
Objective: We previously constructed a quantitative systems pharmacology (QSP) model of Parkinson’s disease (PD) that combines pathogenesis and spatial propagation of misfolded α-synuclein (Asyn) [1].…Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson’s Disease
Objective: To investigate the effect of exogenous ketone ester supplementation on motor and non-motor symptoms in Parkinson’s Disease (PD). Background: Animal research and human pilot…CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform
Objective: Development of a treatment for nocturnal and early morning OFF symptomology in Parkinson’s disease. Background: Levodopa Parkinson’s disease (PD) treatment is limited by its…SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models
Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…Validation of a real- time monitoring system to detect motor symptoms in patients with Parkinson´s disease treated with Levodopa Carbidopa Intestinal Gel
Objective: Our aim was to analyze the ability of system to combine information on OFF periods, falls and dyskinesias of patients with PD. Background: Levodopa…Effect of oxytocin on response inhibition in Parkinson´s disease: a pilot study
Objective: To observe the effect of oxytocin (OXT) on response inhibition in Parkinson´s disease (PD) patients using dedicated saccadic tasks. Background: Cumulating evidence has shown…Comparison of Antiparkinsonian Medication Initiation and Levodopa-Equivalent Daily Dose Across PPMI, STEADY-PD III, and SURE-PD3
Objective: To compare use of antiparkinsonian medications (APM) among early Parkinson disease (PD) patients across clinical study cohorts. Background: Initiation of APM is a key…VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS
Objective: Because neuromelanin derives from the oxidation of free cytosolic dopamine, we hypothesized that enhancing dopamine vesicular encapsulation with vesicular monoamine transporter 2 (VMAT2) will…
- « Previous Page
- 1
- …
- 740
- 741
- 742
- 743
- 744
- …
- 1734
- Next Page »